



Page: 1/5

Dear contributors, colleagues and co-workers,

I sincerely hope that the difficult current situation is not affecting your lives too much, and that you all have been healthy and safe. Before the start of summer and the holiday period, I wish to give you some information about the SENOMAC trial and the recent safety analysis. Until June 8, we had together randomised 1974 patients (see following figures).



Number of randomisations per month



Cumulative number of randomisations from start of trial

The independent safety analysis of 1794 included patients took place on May 12, 2020. The safety committee assessed the trial progress to be stable and adequate with most patients randomised in Sweden and Denmark. There were few overall deaths (N=28), 18 of which were caused by breast cancer, and 48 breast cancer recurrences. Comparing the two groups in a blinded fashion, overall survival tended to be better in one group without reaching statistical significance (p=0.053). In addition, patients of both groups who were operated by mastectomy had a lower overall and breast cancer-specific survival than those operated by breast-conserving surgery, but again without reaching statistical significance (p=0.051 and p=0.140, respectively).

The safety committee recommended the following:

- 1. Continue enrolment for at least another year
- 2. Perform an additional safety analysis in May 2021
- 3. Change main endpoint to overall survival

This means we will continue the trial and update the protocol with a revised statistical sample size calculation within short. It also means that we should do everything we can to increase enrolment, especially at sites with currently low enrolment rates. I wish to ask you all to discuss in your teams how you can increase your local enrolment rate so that we can bring this trial forward together.

I thank you all for your efforts for the SENOMAC trial despite the changes in practice and workload that the corona crisis has brought over us.

Please consider the following table and figure, and please share this newsletter with your colleagues and co-workers.

My best wishes for all of you,

Jana de Boniface,

for the SENOMAC steering committee and the sponsor Karolinska Institutet.

jana.de-boniface@ki.se or jana.de-boniface@capiostgoran.se

Page: 3/5

Table: Number of site-specific randomisations as of June 8, 2020

Please observe that this table only shows those sites that have generated randomisations as of 2020JUN8. For a list of all initiated sites, please see the trial homepage.

Site	Country	Initiation visit	First patient in	Number of randomisations
Västerås	Sweden	2015-03-02	2015-04-14	49
S:t Göran	Sweden	2015-03-05	2016-06-07	153
Akademiska Uppsala	Sweden	2015-03-12	2016-02-14	47
Södersjukhuset	Sweden	2015-03-18	2015-11-24	112
Örebro	Sweden	2015-03-25	2015-10-01	49
Sahlgrenska	Sweden	2015-04-23	2015-06-10	96
Lund/Malmö	Sweden	2015-05-13	2015-10-13	103
Helsingborg	Sweden	2015-05-20	2015-07-23	44
Linköping	Sweden	2015-05-27	2016-11-03	85
Karlstad	Sweden	2015-05-28	2015-12-14	36
Lidköping/Skövde	Sweden	2015-06-04	2015-10-22	75
Uddevalla	Sweden	2015-06-04	2015-09-21	23
Kalmar	Sweden	2015-09-02	2016-03-03	16
Västervik	Sweden	2015-09-02	2016-02-18	30
Karlskrona	Sweden	2015-09-03	2015-12-14	6
Gävle	Sweden	2015-09-10	2015-12-30	38
Sundsvall	Sweden	2015-10-15	2015-10-29	54
Umeå	Sweden	2015-11-19	2016-02-10	47
Halmstad/Varberg	Sweden	2015-12-10	2016-02-17	27
Växjö	Sweden	2016-01-14	2016-03-23	35
Aarhus	Denmark	2016-11-28	2017-04-25	90
Randers	Denmark	2017-09-14	2017-11-07	18
Köpenhamn	Denmark	2016-12-19	2017-04-20	186
Rigshospitalet/Herlev				
Jönköping	Sweden	2017-01-20	2017-11-13	34
Kristianstad	Sweden	2017-03-20	2017-05-17	38
Borås	Sweden	2017-02-20	2018-09-14	7
Aabenraa	Denmark	2017-10-12	2017-12-13	53
Odense	Denmark	2017-11-22	2018-02-16	35
Esbjerg	Denmark	2017-12-12	2018-03-05	9
Viborg	Denmark	2017-11-03	2018-03-16	54
Aalborg	Denmark	2017-10-10	2018-02-07	66
Bad Langensalza	Germany	2018-04-04	2018-05-23	4
Rostock	Germany	2018-03-12	2018-06-07	11
Berlin Spandau	Germany	2018-04-19	2018-09-07	3
Laiko 1, Athens	Greece	2018-06-28	2018-10-12	9

Vejle	Danmark	2018-03-19	2018-11-07	41
Esslingen	Germany	2018-02-16	2018-10-26	2
Klinikum Kassel	Germany	2018-06-12	2018-11-22	1
Heraklion, Crete	Greece	2019-02-19	2019-03-07	7
Athens Euroclinic	Greece	2019-12-11	2019-02-12	5
Dresden	Germany	2018-05-02	2019-03-01	6
Hanau	Germany	2018-05-18	2019-02-12	8
Karlsruhe	Germany	2018-07-11	2018-12-18	1
Villingen-	Germany	2018-09-10	2018-12-28	1
Schwenningen				
Mittelbaden	Germany	2018-08-16	2019-03-13	3
Laiko 2, Athens	Greece	2018-11-07	2019-05-29	4
San Raffaele Milano	Italy	2018-02-01	2019-05-21	4
IEO Milano	Italy	2019-05-06	2019-06-06	16
Unna	Germany	2018-03-01	2019-05-28	5
Ebersberg	Germany	2018-04-10	2019-04-06	2
Stendal	Germany	2018-04-25	2019-05-14	1
Wiesbaden St. Josef	Germany	2018-06-14	2019-05-03	1
Worms	Germany	2018-08-28	2019-05-02	1
Potsdam	Germany	2019-06-18	2019-07-01	3
Tübingen	Germany	2019-09-04	2019-09-24	6
Böblingen	Germany	2018-07-10	2019-11-07	2
Wiesbaden Asklepios	Germany	2019-11-27	2020-01-28	2
Dresden St Joseph	Germany	2019-10-08	2020-05-18	1
Bochum	Germany	2018-02-07	2020-05-05	2
Total				1974

Page: 5/5

Figure: Accumulated site-specific inclusion (only sites generating randomisations as of June 8, 2020 are shown).

